“It's not unusual for complex disorders to have combination therapies,” says Martin Kolb, MD, PhD, professor of medicine at McMaster University.
Martin Kolb, MD, PhD, professor of medicine at McMaster University, envisions a future where most patients with idiopathic pulmonary fibrosis (IPF) may require combination therapies involving multiple drugs. In this interview, he highlights the significance of upcoming clinical trial results, such as those for nerandomilast, in shaping the treatment landscape.
Kolb also serves as a pulmonary physician and director of research at the Firestone Institute for Respiratory Health at St. Joseph’s Healthcare, as well as Jack Gauldie Boehringer Ingelheim Chair in Interstitial Lung Disease.
Transcript
With the promising signs shown by PDE4B inhibitors in treating IPF, what are your hopes for the future landscape of IPF treatment?
The future will probably mean that you will have combination therapies for most patients. Maybe not all of them, there are people who are stable on just 1 drug now. But most people will probably need some kind of combination, if it's a combination of 1 or 2 or 3 drugs or even more, that's to be shown. It's not unusual for complex disorders to have combination therapies, so we will be getting there too for IPF and other pulmonary fibrosis types. If it's nerandomilast or others, that will be shown.
Nerandomilast is certainly probably the next one where we get big news, so we'll see if it's good news for the patients. But it's a very well-done, big clinical trial with a large number of patients, and it will give us an answer. And it will give us not an indeterminate answer, it will show us it works or it doesn't work, and that's important. I mean, of course we all hope for good outcomes here regardless, for the patient side and the physician and the health care provider, so anyone will hope that this goes through, but we'll find out.
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More